PATOU GARY 4

What Happened

Gary Patou, a director of Xenon Pharmaceuticals (XENE), sold 1,322 shares on June 5, 2026. The shares were disposed at $53.14 per share for a total transaction value of $70,251. The sale was reported on a Form 4 filed June 8, 2026.

Key Details

• Transaction type: Sale (open-market), code S
• Date of transaction: 2026-06-05
• Price per share: $53.14; Shares sold: 1,322; Total proceeds: $70,251
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes:
  • F1: Sale effected pursuant to a Rule 10b5-1 trading plan adopted Aug 17, 2025 to satisfy tax obligations from RSUs granted June 5, 2025.
  • F2: Transaction executed by/through the Patou Family Trust (Gary & Karen Barbara Patou, Trustee).
• Filing: Form 4 filed 2026-06-08; no late-filing indication in the summary provided.

Context

This sale was made under a pre-established 10b5-1 plan to cover tax obligations tied to RSU vesting, which commonly explains routine insider sales and should not be read on its own as a signal of management sentiment. For retail investors, purchases by insiders typically carry more emphasis than routine sales; always consider insider trades alongside company fundamentals and broader market activity.